First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.

Thumbnail Image
View / Download3.29 MB

Date

2018-08

Authors

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

32
views
10
downloads

Citation Stats

Abstract

Introduction

Maximizing extent of surgical resection with the least morbidity remains critical for survival in glioblastoma patients, and we hypothesize that it can be improved by enhancements in intraoperative tumor detection. In a clinical study, we determined if therapeutic antibodies could be repurposed for intraoperative imaging during resection.

Methods

Fluorescently labeled cetuximab-IRDye800 was systemically administered to three patients 2 days prior to surgery. Near-infrared fluorescence imaging of tumor and histologically negative peri-tumoral tissue was performed intraoperatively and ex vivo. Fluorescence was measured as mean fluorescence intensity (MFI), and tumor-to-background ratios (TBRs) were calculated by comparing MFIs of tumor and histologically uninvolved tissue.

Results

The mean TBR was significantly higher in tumor tissue of contrast-enhancing (CE) tumors on preoperative imaging (4.0 ± 0.5) compared to non-CE tumors (1.2 ± 0.3; p = 0.02). The TBR was higher at a 100 mg dose than at 50 mg (4.3 vs. 3.6). The smallest detectable tumor volume in a closed-field setting was 70 mg with 50 mg of dye and 10 mg with 100 mg. On sections of paraffin embedded tissues, fluorescence positively correlated with histological evidence of tumor. Sensitivity and specificity of tumor fluorescence for viable tumor detection was calculated and fluorescence was found to be highly sensitive (73.0% for 50 mg dose, 98.2% for 100 mg dose) and specific (66.3% for 50 mg dose, 69.8% for 100 mg dose) for viable tumor tissue in CE tumors while normal peri-tumoral tissue showed minimal fluorescence.

Conclusion

This first-in-human study demonstrates the feasibility and safety of antibody based imaging for CE glioblastomas.

Type

Journal article

Department

Description

Provenance

Subjects

Brain, Humans, Glioblastoma, Brain Neoplasms, Indoles, Fluorescent Dyes, Spectroscopy, Near-Infrared, Surgery, Computer-Assisted, Sensitivity and Specificity, Dose-Response Relationship, Drug, Optical Imaging, Cetuximab, Antineoplastic Agents, Immunological

Citation

Permalink

https://hdl.handle.net/10161/25899

Published Version (Please cite this version)

10.1007/s11060-018-2854-0

Publication Info

Miller, Sarah E, Willemieke S Tummers, Nutte Teraphongphom, Nynke S van den Berg, Alifia Hasan, Robert D Ertsey, Seema Nagpal, Lawrence D Recht, et al. (2018). First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800. Journal of neuro-oncology, 139(1). pp. 135–143. 10.1007/s11060-018-2854-0 Retrieved from https://hdl.handle.net/10161/25899.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Collections

Scholarly Articles
Full item page

Scholars@Duke

Grant

Gerald Arthur Grant

Allan H. Friedman Distinguished Professor of Neurosurgery

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.